Drug Trial Radar · NCT07611747
Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,117
Planned (sponsor's estimate)
Start
Apr 22, 2026
Primary completion
Apr 22, 2031
Study completion Dec 2031
Sponsor
- Lead sponsor
- Instituto de Investigación Marqués de ValdecillaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PREVENER is a randomized, open-label, multicenter, phase IV clinical trial designed to evaluate the efficacy and safety of a carotid ultrasound-based strategy for the primary prevention of cardiovascular events in patients with inflammatory rheumatic diseases (IRD). Patients with IRD, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (AxSpA), and systemic lupus erythematosus (SLE), have a 50% higher risk of cardiovascular (CV) events compared to the general population. However, conventional CV risk scores (SCORE2/OP) systematically underestimate this risk, leaving many high-risk patients without appropriate preventive treatment. Patients aged ≥50 years with IRD and low-to-moderate CV risk according to SCORE2/OP will be randomized 1:1 to either an experimental group (carotid ultrasound to detect subclinical atherosclerosis) or a control group (standard care according to ESC 2021 guidelines). Patients in the experimental group with carotid plaques will be reclassified as very high CV risk and treated with high-intensity statins (LDL target \<55 mg/dL). The primary endpoint is the incidence of major adverse cardiovascular events (MACE) over 48 months of follow-up.
Conditions
- Rheumatoid Arthritis (RA)
- Psoriatic Arthritis (PsA)
- Systemic Lupus Erythematosus (SLE)
- Carotid Artery Diseases
- Cardio Vascular Disease
- Atheroscleroses
- Axial Spondyloarthritis
Interventions
Carotid UltrasoundDiagnostic test
Carotid ultrasound performed to detect subclinical atherosclerosis (carotid plaques) according to Mannheim consensus criteria. The presence of carotid plaques triggers reclassification to very high cardiovascular risk and initiation of high-intensity lipid-lowering therapy.
High-intensity lipid-lowering therapyDrug
Sequential lipid-lowering therapy initiated in experimental group patients with carotid plaques, targeting LDL \< 55 mg/dL. Treatment includes high-intensity statins (atorvastatin 40-80mg, rosuvastatin 20-40mg), with possible addition of ezetimibe, bempedoic acid, and/or PCSK9 inhibitors if target is not achieved.
Standard care according to ESC 2021 guidelinesOther
Lipid-lowering treatment indicated and managed according to ESC 2021 cardiovascular prevention guidelines, based on SCORE2/OP risk stratification, without carotid ultrasound assessment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Major Adverse Cardiovascular Events (MACE)Time frame: 48 months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitario Araba
Vitoria-Gasteiz, Álava, Spain · Recruiting
Hospital Universitario de Elche
Elche, Alicante, Spain · Recruiting
Hospital Vega Baja de Orihuela
Orihuela, Alicante, Spain · Recruiting
Hospital Universitario San Juan de Alicante
Sant Joan d'Alacant, Alicante, Spain · Recruiting
Hospital Universitario Vall d'Hebrón
Barcelona, Barcelona, Spain · Recruiting
Hospital de Laredo
Laredo, Cantabria, Spain · Recruiting
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain · Recruiting
Hospital Sierrallana
Torrelavega, Cantabria, Spain · Recruiting
Hospital General Universitario de Ciudad Real
Ciudad Real, Ciudad Real, Spain · Recruiting
Hospital Universitario Reina Sofía
Córdoba, Córdoba, Spain · Recruiting
Hospital Universitari Son LLàtzer
Palma, Isla Baleares, Spain · Recruiting
Hospital Universitario de Gran Canaria Dr. Negrín
Las Palmas de Gran Canaria, Las Palmas, Spain · Not yet recruiting
Hospital Universitario La Paz
Madrid, Madrid, Spain · Recruiting
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Spain · Recruiting
Hospital Universitario Virgen de la Arrixaca
Murcia, Murcia, Spain · Recruiting
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain · Recruiting
Hospital Universitario de Basurto
Bilbao, Vizcaya, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.